We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Discovery Laboratories, Inc. (MM) | NASDAQ:DSCOD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.11 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
Discovery Laboratories Inc. (DSCOD) said it could be able to file a complete response with the U.S. Food and Drug Administration early in the third quarter on Surfaxin, its experimental preventative drug for respiratory distress syndrome in premature infants.
The drug developer, which had said in June the filing was on track for the first quarter, now says it has had multiple discussions with the agency regarding tests on the drug.
Like many drug developers, Discovery Labs has been unprofitable as it generates no revenue. It enacted a 1-for-15 reverse stock split last month in order to keep its Nasdaq listing and earlier this year sold stock and warrants, seeking proceeds for research and development.
Shares were down 1.9% at $3.63 in premarket activity.
-By Matt Jarzemsky, Dow Jones Newswires; 212-416-2240; matthew.jarzemsky@dowjones.com
1 Year Discovery Laboratories, Inc. (MM) Chart |
1 Month Discovery Laboratories, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
